Prolonged, complete remission after 2-chiorodeoxyadenosine therapy in a patient with refractory essential mixed cryoglobulinemia

Mayo Clinic Proceedings

Volumn 71, Issue 10, 1996, Pages 966-968

  Lee, Thomas C ^a   Miller, William E ^a   Curd, John G ^b   Piro, Lawrence D ^b   Saven, Alan ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b GENENTECH INC   (United States)

Author keywords

2 cda = 2 chlorodeoxyadenosine

Indexed keywords

ALPHA2 INTERFERON; CLADRIBINE; CYCLOPHOSPHAMIDE; PREDNISONE; VINCRISTINE SULFATE;

AGED; ARTICLE; CASE REPORT; CLINICAL PROTOCOL; CORTICOSTEROID THERAPY; CRYOGLOBULINEMIA; DISEASE ASSOCIATION; DRUG MEGADOSE; GLOMERULONEPHRITIS; HEPATITIS C; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNOTHERAPY; MALE; RECURRENT DISEASE; TREATMENT PLANNING; VASCULITIS;

EID: 0030317089     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/71.10.966     Document Type: Article

References (13)

1. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med 1974; 57:775-788
2. Gorevic PD, Kassab HJ, Levo Y, Kohn R, Meltzer M, Prose P, et al. Mixed cryoglobulinemia: clinical aspects and longterm follow-up of 40 patients. Am J Med 1980; 69:287308
3. Misiani R, Bellavita P, Fenili D, Vicari O, Marches! D, Sironi PL, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994; 330:751-756
4. Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994; 330:691-697
5. Kay AC, Saven A, Carrera CJ, Carson DA, Thurston D, Beutler E, et al. 2-Chlorodeoxyadenosine treatment of lowgrade lymphomas. JClinOncol 1992; 10:371-377
6. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD. 2Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk Lymphoma 1991; 5(Suppl):133138
7. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, et al. Treatment of Waldenström macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118:195-198
8. Saven A, Emanuele S, Kosty M, Koziol J, Ellison D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 1995; 86:17101716
9. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62:737-743
10. Dimopoulos MA, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin [letter]. Am J Hematol 1993; 43:326-327
11. Golomb HM, Jacobs A, Fefer A, Ozer H, Thompson J, Portlock C, et al. Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients. J Clin Oncol 1986; 4:900-905
12. Carrera CJ, Piro LD, Saven A, Cox K, Beutler E, Carson DA, et al. Restoration of lymphocyte subsets following 2chlorodeoxyadenosine remission induction in hairy cell leukemia [abstract]. Blood 1990; 76(Suppl l):260a
13. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R, et al. Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149:3339-3344